Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.

@article{Elens2013ImpactOC,
  title={Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.},
  author={Laure L Elens and Arnaud Capron and Ron H. N. van Schaik and Martine de Meyer and Luc de Pauw and Djamila Chaib Eddour and Dominique Latinne and Pierre E Wallemacq and M. Hussein Mourad and Vincent Haufroid},
  journal={Therapeutic drug monitoring},
  year={2013},
  volume={35 5},
  pages={608-16}
}
BACKGROUND Tacrolimus (Tac) metabolism is mainly mediated by the cytochrome P450 3A (CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying the CYP3A4*22 decrease-of-function allele require lower Tac doses and are more at risk of Tac overexposure than CYP3A4*1/*1 patients. This effect was shown to be independent of the CYP3A5*3 allelic status. However, the pharmacokinetic (PK) parameters assessed in previous studies were limited on single time point whole… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…